Eight Pro Tips to Help Patients With Skin Diseases Look Their Best

August 7, 2025

What Is Broc Shot? Get to Know the First Supplement to Ever Receive the NPF’s Seal of Recognition

August 1, 2025

J&J Asks FDA to Add PsA Joint Damage Inhibition Data to Guselkumab (Tremfya) Label

July 30, 2025

Immune Drift: A Guide to Understanding Mechanisms by Biologic Class

July 29, 2025

Johnson & Johnson Submits NDA for Oral Icotrokinra in Plaque Psoriasis

July 22, 2025

U.S. FDA Accepts Supplemental New Drug Application for Deucravacitinib (Sotyktu, Bristol Myers Squibb) in PsA

July 21, 2025

Boehringer Ingelheim and LEO Pharma Partner to Commercialize and Further Develop IL-36 Blocker Spesolimab (Spevigo)

July 14, 2025

Hawaii Tops List of States With the Most Google Searches for Skin Conditions and Treatments

July 8, 2025

Bimekizumab (Bimzelx, UCB) Shows Lasting Efficacy in Phase 3 PsA Study

June 11, 2025

Guselkumab (Tremfya, Johnson & Johnson) Inhibits Progression of Joint Damage in PsA

June 11, 2025

Belly Fat More Strongly Linked to PsO Risk; Findings Highlight Role for GLP1-RAs in PsO

June 3, 2025

LEO Pharma Initiates Phase 2a Trial of Delgocitinib Cream in Adults With PPP

June 3, 2025